About Visikol®
Visikol® is a Healthcare company based in New Brunswick (United States) founded in 2012, and was acquired by Sartorius in April 2025. Optical clearing agents for tissue transparency are developed by Visikol. Visikol® has raised $500 thousand across 8 funding rounds from investors including Sartorius, HHS and CELLINK. The company has 29 employees. Its website visikol.com draws about 15 thousand monthly visits. Visikol® offers products and services including In Vitro Assay Services, Tissue Imaging Services, and High Content Screening. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is Visikol, Inc. Its competitors include Avidity Biosciences, Sutro Biopharma and Antheia; 3 of its 3 listed competitors have raised funding.
Company details
Visikol was founded in 2012 in New Brunswick, United States, and operates in the biotechnology sector. Optical clearing agents, such as the product Visikol, are developed to penetrate tissues and achieve transparency without structural damage. These agents support 3D visualization in applications including toxicology, pre-clinical drug development, clinical diagnostics, basic research, and plant biology. The companys domain is visikol.com.
- Headquarters New Brunswick, United States
- Employees 29
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website visikol.com
- Social LinkedIn X Facebook
- Acquired by Sartorius (Apr 2025)
- Legal Name Visikol, Inc.
Products & Services of Visikol®
Visikol® offers a comprehensive portfolio of products and services, including In Vitro Assay Services, Tissue Imaging Services, and High Content Screening.
Advanced assays for cell proliferation and toxicity testing.
High-content screening and 3D analysis for drug research.
Screening for cellular responses in drug development.
Funding Insights of Visikol®
Visikol® has successfully raised a total of $500K across 8 strategic funding rounds. The most recent funding activity was a Grant round of $1.63 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $500,000
- Total Rounds 8
- Last Round Grant — $1.63M
- First Round $500,000
(Feb 2016)
- Investors Count 7
All 8 funding rounds of Visikol with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2021 | $1.63M | Grant | – | – | |
| Apr 2019 | $949,999 | Grant | – | – | |
| Aug 2018 | $224,526 | Grant | – | – | |
| Apr 2018 | Angel Round | – | James M Golubieski | – | |
| Jan 2018 | Angel Round | – | – | ||
| Jul 2016 | $225,000 | Grant | – | – | |
| Feb 2016 | $50,000 | Grant | – | – | |
| Feb 2016 | $500,000 | Seed | – | – |
9 investors in total: 6 institutional and 3 angel.
Investors in Visikol®
Visikol® has secured backing from 9 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Sartorius, HHS and CELLINK.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund backed by the US Government | seedfund.nsf.gov | Alexandria, United States | ||
| foundationventure.com | ||||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States | |
Laboratory and biopharmaceutical equipment is developed for production processes. | 1870 | sartorius.com | Gottingen, Germany | |
JM James M Golubieski | Angel investor with focus on Indian startups, experienced in finance. | unknown_d6ef3c584e2444c4b | ||
BM Brian Mulhall | unknown_810a7580f83d4e1fa | |||
AW Alan Weiss | unknown_e29cfb83ec0942f8b | |||
3D bioprinters and bioinks are developed for research applications. | 2016 | cellink.com | Boston, United States |
Investor details for Visikol
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Visikol®
6 people are tracked at Visikol® (2 in leadership, 4 in team); the tracked headcount is 29.
| Name | Role | Group |
|---|---|---|
Carol Tomaszewski | Director of Marketing | Leadership |
Megan Casco | Director Of In Vitro And Histology | Leadership |
Sean McInnes | Human Resource Manager | Team |
Katie Worley, Ph.D. | Senior Principal Scientist | Team |
Jigar Patel | Principal Analyst | Team |
Qili Yu | Scientist | Team |
Complete people profiles for Visikol®
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of Visikol®
Visikol® has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Antheia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. |
Detailed competitors of Visikol
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Visikol®
The website of Visikol® (visikol.com) receives about 14.9K visits a month.
- Monthly visits14.9K
▲ 4.5% vs previous month
Websites whose visitors overlap most with Visikol®. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
thno.org | thno.org | 100% | #313,981 | – | |
| biocare.net | 98% | 23.2K | #1,197,634 | View details | |
| corning.com | 85% | 606.5K | #95,499 | View details | |
| hellobio.com | 84% | 55.4K | #653,889 | View details | |
| precisionary.com | 81% | #2,503,320 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 18 similar websites and full traffic analytics for Visikol®
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 18 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Visikol® (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Visikol®
Complete news archive for Visikol
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Visikol®
Visikol® was founded in 2012 and raised its 1st funding round 4 years after it was founded.
Visikol® is headquartered in New Brunswick, United States. It is registered at New Brunswick, New Jersey, United States.
Visikol® is a funded company, having raised a total of $500K across 8 funding rounds to date. The company's 1st funding round was a Seed of $500K, raised on Feb 2016.
Visikol® has 29 employees.
Visikol was founded in 2012 in New Brunswick, United States, and operates in the biotechnology sector. Optical clearing agents, such as the product Visikol, are developed to penetrate tissues and achieve transparency without structural damage. These agents support 3D visualization in applications including toxicology, pre-clinical drug development, clinical diagnostics, basic research, and plant biology. The companys domain is visikol.com.
Visikol®'s top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Visikol® offers In Vitro Assay Services, Tissue Imaging Services, and High Content Screening.
Visikol® has 9 investors. Key investors include Sartorius, HHS, CELLINK, America’s Seed Fund, and James M Golubieski.
Visikol® operates through Visikol, Inc..
Yes. Visikol® was acquired by Sartorius in April 2025.